TY - JOUR
T1 - Use of 7.5 mg/kg of bevacizumab to palliate symptomatic malignant ascites in recurrent ovarian cancer
AU - Shimizu, Y.
AU - Nakanishi, T.
AU - Sasamoto, K.
AU - Kondo, S.
N1 - Publisher Copyright:
© 2018 S.O.G. Canada Inc. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Purpose: To investigate the effectiveness of single-agent intravenous bevacizumab (7.5 mg/kg every three to four weeks) for palliating symptomatic malignant ascites caused by recurrent ovarian cancer, the authors examined the cases retrospectively. Materials and Methods: Five patients with recurrent ovarian cancer and malignant ascites were treated with bevacizumab. Results: A total of 23 bevacizumab infusions were administered for the patients, and the mean inter-infusion interval was 26.1 days (range: 21-35). After one course of therapy, no further paracentesis was required in four patients. However, bevacizumab was not effective in one patient and hence paracentesis had to be repeated. Due to disease progression, treatment was aborted in four patients, who died of their disease within a few months of the bevacizumab treatment (median overall survival period: 3.3 months). Conclusion: The intravenous infusion of 7.5 mg/kg bevacizumab at three- to four-week intervals is a promising therapy for malignant ascites caused by recurrent ovarian cancer.
AB - Purpose: To investigate the effectiveness of single-agent intravenous bevacizumab (7.5 mg/kg every three to four weeks) for palliating symptomatic malignant ascites caused by recurrent ovarian cancer, the authors examined the cases retrospectively. Materials and Methods: Five patients with recurrent ovarian cancer and malignant ascites were treated with bevacizumab. Results: A total of 23 bevacizumab infusions were administered for the patients, and the mean inter-infusion interval was 26.1 days (range: 21-35). After one course of therapy, no further paracentesis was required in four patients. However, bevacizumab was not effective in one patient and hence paracentesis had to be repeated. Due to disease progression, treatment was aborted in four patients, who died of their disease within a few months of the bevacizumab treatment (median overall survival period: 3.3 months). Conclusion: The intravenous infusion of 7.5 mg/kg bevacizumab at three- to four-week intervals is a promising therapy for malignant ascites caused by recurrent ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=85049750566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049750566&partnerID=8YFLogxK
U2 - 10.12892/ejgo3776.2018
DO - 10.12892/ejgo3776.2018
M3 - Article
AN - SCOPUS:85049750566
SN - 0392-2936
VL - 39
SP - 404
EP - 407
JO - European Journal of Gynaecological Oncology
JF - European Journal of Gynaecological Oncology
IS - 3
ER -